PHA 2026 Poster Abstracts
|
Search / Filter
|
|
|
A Randomized, Double-Blind, Placebo-Controlled Study of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Arterial Hypertension
Speaker(s): Larisa Ruiz Serrano, PharmD, Insmed Incorporated
Session Code: 1012
|
Session Code: 1012
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
A tale of two fistulas: Two Cases of Pulmonary Hypertension Associated in a patient with End Stage Renal Disease (ESRD) on Hemodialysis (HD) via an Arteriovenous Fistula (AVF)
Speaker(s): Nisha Puri, DO, MPH Dhriti Shah, Bachelors of Science in Biology, Medical University of South Carolina College of Medicine
Session Code: 1058
|
Session Code: 1058
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Acute Right Ventricular Failure Following Scalp AVM Embolization: A Case of Non-Thrombotic Pulmonary Microembolism
Speaker(s): Ahmed Abdelmonem, MD, Baylor University Medical Center
Session Code: 1053
|
Session Code: 1053
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Advancing Careers and Leadership in Pulmonary Hypertension: Key Insights From PH Clinicians
Speaker(s): Roxana Sulica, MD, NYU Langone Health
Session Code: 1048
|
Session Code: 1048
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BA1B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Alterations of Lung Microbiota in Adults with Atrial Septal Defect-Associated Pulmonary Hypertension
Speaker(s): Jiahong Li, Bachelor of Clinical Medicine, Guangdong Provincial People's Hospital
Session Code: 1017
|
Session Code: 1017
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Alternative Basilic / Brachial, performed by Vein Access for right Heart Catheterization in PAH high risk patients
Speaker(s): Guillermo Bortman, MD PHP, Sanatorio Trinidad Mitre
Session Code: 1032
|
Session Code: 1032
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Analysis of TAC1 Promoter Methylation as a Potential Epigenetic Marker in the Progression from Acute Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension.
Speaker(s): Leslie Marisol Gonzalez-Hermosillo, 13508970, UNAM Posgrado
Session Code: 1077
|
Session Code: 1077
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Approach to Mixed Pulmonary Hypertension In sarcoidosis with bioprosthetic mitral valve disease
Speaker(s): Ozdemir Erdemir, MD, Temple University Hospital
Session Code: 1041
|
Session Code: 1041
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Association Between Pulmonary Hemodynamics, Primary Graft Dysfunction, and Survival in Contemporary Bilateral Lung Transplant
Speaker(s): Alex Tang, MD, Cedars-Sinai Medical Center
Session Code: 1031
|
Session Code: 1031
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Bleeding outcomes in patients taking sotatercept for pulmonary hypertension
Speaker(s): Uma Gude, M.Sc., University of Texas Southwestern Medical Center
Session Code: 1057
|
Session Code: 1057
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Burden of Pulmonary Hypertension in Obstructive Sleep Apnea: Correlation with Disease Severity and Quality of Life
Speaker(s): Jyoti Bajpai, MD RESPIRATORY MEDICINE, KING GEORGE'S MEDICAL UNIVERSITY LUCKNOW ,INDIA
Session Code: 1047
|
Session Code: 1047
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Clinical Characteristics and Treatment Patterns in US Medicare Patients With Pulmonary Arterial Hypertension (PAH) Receiving Selexipag or Treprostinil
Speaker(s): Robert Martin, PharmD, Insmed Inc
Session Code: 1010
|
Session Code: 1010
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Comparative Efficacy of Levosimendan Versus Milrinone in Adults with Pulmonary Hypertension: A Systematic Review and Meta-Analysis
Speaker(s): Siddhanta K C, MD, Lankenau medical Center
Session Code: 1004
|
Session Code: 1004
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Connecting the Virtual Gap: Does Format Matter in Tele-Rehabilitation for Adolescents with PH?
Speaker(s): Aimee Layton, PhD, Columbia University Medical Center
Session Code: 1033
|
Session Code: 1033
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B71B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
De-escalation of prostacyclin analogue therapy after initiation of sotatercept in patients with pulmonary arterial hypertension
Speaker(s): Jane Wang, MD, Washington University in St. Louis
Session Code: 1052
|
Session Code: 1052
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Delays in Hospital Discharge Due to Lack of Adequate Home Oxygen Systems
Speaker(s): Colleen Connor Nicholas Kolaitis, MD, MAS, University of California, San Francisco Medical Center Katie Kroner, Pulmonary Hypertension Association
Session Code: 1082
|
Session Code: 1082
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Design and evaluation of novel oral 4-MU formulations to maximize systemic exposure for the treatment of Group 3 Pulmonary Hypertension (PH-ILD)
Speaker(s): Rudy Paladini, PhD, Halo Biosciences, Inc.
Session Code: 1074
|
Session Code: 1074
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Development and Implementation of a Comprehensive Pulmonary Hypertension Patient Education Resource Using a Novel Approach: Patients and Caregivers Take the Lead
Speaker(s): Susanne McDevitt, DNP, ACNP-BC, University of Michigan
Session Code: 1070
|
Session Code: 1070
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BA1B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Dose-Anchored Conversion of IV Treprostinil to Oral Selexipag: A Case Report with Literature Review
Speaker(s): Smitesh Padte, MD, WellSpan York Hospital
Session Code: 1007
|
Session Code: 1007
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Endothelium Collection from Pulmonary Artery Balloon Catheter in Children
Speaker(s): Maxwell Mathias, MD, University of Oklahoma Health Campus
Session Code: 1073
|
Session Code: 1073
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Examining Undertreatment and Delays in Therapy for Pulmonary Arterial Hypertension: A Real-world Patient Journey Study from the US
Speaker(s): Charles Burger, MD, Mayo Clinic in Florida
Session Code: 1038
|
Session Code: 1038
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1076
|
Session Code: 1076
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Fatal Strain: Two Cases of Sudden Cardiac Death During Straining in Pulmonary Arterial Hypertension
Speaker(s): Karol Kamel, MD, Santa Barbara Cottage Hospital Ximena Chavarria, MD
Session Code: 1068
|
Session Code: 1068
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
GLP1 AGONIST USE IN OBESITY IS ASSOCIATED WITH LOWER RISK OF INCIDENT PULMONARY HYPERTENSION, HEART FAILURE AND MORTALITY
Speaker(s): Pushan Aggarwal, MD, Allegheny General Hospital
Session Code: 1019
|
Session Code: 1019
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
GLP1 AGONISTS IN PATIENTS WITH DIABETES: EVALUATING INCIDENT PULMONARY HYPERTENSION WITH REAL WORLD DATA
Speaker(s): Pushan Aggarwal, MD, Allegheny General Hospital
Session Code: 1020
|
Session Code: 1020
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Gaps Between Diagnosis and Definitive Care in Pulmonary Hypertension in Low-Resource Settings: Clinical Consequences and a Patient-Led Facilitation Approach
Speaker(s): Chooda Khanal, Ph.D., PHA Nepal Hriman Khanal, Grade 10, Pulmonary Hypertension Association Nepal George Bush Jung Katwal, MBBS, Pulmonary Hypertension Association Nepal
Session Code: 1054
|
Session Code: 1054
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1036
|
Session Code: 1036
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1037
|
Session Code: 1037
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Hearing from Patients: Self-Reported Cough Outcomes During Treatment with YUTREPIA™ (treprostinil) in the ASCENT Trial
Speaker(s): Seth Hall, MBA, RRT, RRT-ACCS, RRT-NPS, Liquidia Technologies
Session Code: 1014
|
Session Code: 1014
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
IMPROVE-PAH: An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Speaker(s): Allison Widlitz, MS, PA-C, Inhibikase Therapeutics, Inc.
Session Code: 1028
|
Session Code: 1028
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Impact of Perfusate Clearance on Pulmonary Vascular Function and Inflammation in Donor Lungs During Ex Vivo Lung Perfusion
Speaker(s): Maira Machhiwala, MBT, University of Alberta
Session Code: 1030
|
Session Code: 1030
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Impact of Socioeconomic Disparities on Clinical Outcomes in Pulmonary Arterial Hypertension (Groups 1 & 4) Using the Area Deprivation Index
Speaker(s): Dafne Moretta, MD, Loma Linda University Medical Center Bilal Malik, MD, Loma Linda University
Session Code: 1078
|
Session Code: 1078
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BB1B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Impact of an Integrated Specialty Pharmacist Care Model on Patient-Reported Quality of Life Outcomes in Pulmonary Hypertension: An Interim Analysis
Speaker(s): Jiaying Li, PharmD, CSP, BCACP, Medical University of South Carolina
Session Code: 1021
|
Session Code: 1021
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Increased Tricuspid Regurgitation on Echocardiography is Associated with Sleep Disordered Breathing in Children with Sickle Cell Disease
Speaker(s): Ammar Alishlash, MD, University of Alabama At Birmingham
Session Code: 1065
|
Session Code: 1065
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B71B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Individualized Exercise Rehabilitation Guided by Cardiopulmonary Exercise Testing Improves Cardiorespiratory Function, Systemic Inflammation, and Quality of Life in Pulmonary Arterial Hypertension
Speaker(s): Shili Zhu, N/A, Shapingba Hospital,Chongqing University
Session Code: 1000
|
Session Code: 1000
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BA1B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Is current pre-operative risk stratification an accurate predictor of postoperative complications in pulmonary hypertension?
Speaker(s): Marc Manzo, MD, Medical College of Georgia
Session Code: 1056
|
Session Code: 1056
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Large Atrial Septal Defect With Severe Pulmonary Arterial Hypertension: Can A “Treat-And-Repair” Approach Be Done During The Same Hospitalization?
Speaker(s): Francisco Soto, MD, MS, MBA, University of Tennessee Medical Center
Session Code: 1062
|
Session Code: 1062
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Long-Term Risk of PH and HF in Women With Hypertensive Disorders of Pregnancy
Speaker(s): Pushan Aggarwal, MD, Allegheny General Hospital
Session Code: 1018
|
Session Code: 1018
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Making it Happen: Enrollment Strategies and Adaptive Trial Designs in PAH
Speaker(s): Peyton Sandroni, PhD, Worldwide Clinical Trials
Session Code: 1035
|
Session Code: 1035
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Microenvironmental Deciphering in Adult Atrial Septal Defect-Associated Pulmonary Arterial Hypertension (ASD-PAH): An Integrated Gut-Lung Microbiome and Metabolome Analysis
Speaker(s): Jiahong Li, Bachelor of Clinical Medicine, Guangdong Provincial People's Hospital
Session Code: 1066
|
Session Code: 1066
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1015
|
Session Code: 1015
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B51B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Not All Pulmonary Vascular Dilations Are AVMs: A Case of Pulmonary Venous Varix in Pulmonary Hypertension
Speaker(s): Sathish Krishnan, MD, FCCP, Community Health Network
Session Code: 1008
|
Session Code: 1008
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
PALM-ILD: Study Design of a Phase 3 Trial of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease
Speaker(s): Vicki Poon, MPH, Insmed Inc.
Session Code: 1011
|
Session Code: 1011
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
PALM-PAH: Study Design of a Phase 3 Trial of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Arterial Hypertension
Speaker(s): Diego Gomes, PhD, Insmed
Session Code: 1013
|
Session Code: 1013
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
PEACE: Preparedness and Emergency Action for Children with Pulmonary Hypertension
Speaker(s): Mary Mullen, MD, PhD, Boston Children's Heart Foundation Inc
Session Code: 1069
|
Session Code: 1069
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B71B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Patient Insights into Subcutaneous Pump Therapy for Pulmonary Arterial Hypertension
Speaker(s): Lauren Janzen, MSN, RN, PCCN, Marquette University
Session Code: 1023
|
Session Code: 1023
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Pharmacokinetics and safety of a novel once-daily treprostinil prodrug transdermal system in humans
Speaker(s): Bobby Singh, Ph.D., Corsair Pharma
Session Code: 1080
|
Session Code: 1080
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Predictive Value of Early NT-proBNP Decline for Hemodynamic Improvement in Sotatercept-Treated Pulmonary Arterial Hypertension
Speaker(s): Meagan Chavarria, AGACNP-BC, Houston Methodist Hospital
Session Code: 1063
|
Session Code: 1063
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Prognostic Utility of the Age-Adjusted Charlson Comorbidity Index in Balloon Pulmonary Angioplasty: A 12-Year Single-Center Experience
Speaker(s): Piotr Szwed, MD, European Health Center
Session Code: 1071
|
Session Code: 1071
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B51B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Pulmonary Hypertension Association Registry (PHAR): A Status Update and Resource for Research
Speaker(s): Charles Burger, MD, Mayo Clinic in Florida
Session Code: 1079
|
Session Code: 1079
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B51B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Pulmonary Hypertension Medication-related Issues on ? Health-related Quality of Life?
Speaker(s): Gillian Leung, PharmD, University of Kentucky Medical Center
Session Code: 1042
|
Session Code: 1042
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Pulmonary Hypertension in Rural Minnesota: Natural History and Outcomes
Speaker(s): Eric Fenstad, MD, MSc, Minneapolis Heart Institute
Session Code: 1002
|
Session Code: 1002
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BB1B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Quality Metrics of Transitioning Patients with PH from Adolescence to Adulthood
Speaker(s): Nelson Reed, MD, Baylor College of Medicine/Texas Children's Hospital
Session Code: 1059
|
Session Code: 1059
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B71B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Real World Experience With Sotatercept Demonstrates Improvements in Right Heart Function and Prostacyclin De-escalation in PAH
Speaker(s): Tamara Freichels, RN, MSN, Aurora St. Luke's Pulmonary Hypertension Clinic
Session Code: 1051
|
Session Code: 1051
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Real-World Utilization of Sotatercept for Pulmonary Hypertension: A Single-Center Retrospective Medication Use Evaluation
Speaker(s): Taylor Moen, PharmD, Atrium Health Kassidy Tucker, PharmD, CPP, Atrium Health Sanger Heart and Vascular Institute
Session Code: 1075
|
Session Code: 1075
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1009
|
Session Code: 1009
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Reversible Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: Sustained Hemodynamic Remission With Immunosuppression
Speaker(s): Varun Bhalla, MD, Icahn School of Medicine at Mount Sinai / NYC H + H (Elmhurst)
Session Code: 1050
|
Session Code: 1050
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Review of explanted histopathology in Combined heart lung transplant to understand the Right heart involvement in severe Sarcoidosis associated Pulmonary Hypertension
Speaker(s): Sana Quddus, MD, Loyola University Medical Center
Session Code: 1046
|
Session Code: 1046
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
SOTATERCEPT IN CONGENITAL HEART DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION AND EISENMENGER SYNDROME: FIRST CASE SERIES
Speaker(s): Gillian Leung, PharmD, University of Kentucky Medical Center
Session Code: 1043
|
Session Code: 1043
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1034
|
Session Code: 1034
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Safety and Exploratory Efficacy data of LIQ861 Dry Powder Inhaled Treprostinil in PH-ILD patients: ASCENT to Week 24
Speaker(s): Savan Patel, MS, Liquidia Technologies
Session Code: 1060
|
Session Code: 1060
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Severe Pulmonary Hypertension Due to Undiagnosed Congenital Heart Disease Presenting in Late Pregnancy
Speaker(s): Maroun Chedid, MD, Minneapolis Heart Institute
Session Code: 1044
|
Session Code: 1044
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Sotatercept in CTEPH for Persistent Pulmonary Hypertension after Pulmonary Thromboendarterectomy and Balloon Pulmonary Angioplasty
Speaker(s): Sandeep Kukreja, MD, MRCP, FCCP, Temple University Hospital Heart and Vascular Institute Mohammed Chowdhury, MD, Temple University
Session Code: 1083
|
Session Code: 1083
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1022
|
Session Code: 1022
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Sotatercept use in patients with pulmonary arterial hypertension and congenital heart disease: an initial case series
Speaker(s): Robin Granberry, MD, UT Southwestern
Session Code: 1025
|
Session Code: 1025
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1064
|
Session Code: 1064
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BB1B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Streamlining Pulmonary Hypertension Care, from Symptoms Onset to Diagnostic Evaluation
Speaker(s): Alexander Schlueter, DO MPH, Kaiser Los Angeles Medical Center
Session Code: 1016
|
Session Code: 1016
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B51B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
The Invisible Burden: Mental Health Challenges Facing Caregivers of Patients with Pulmonary Hypertension
Speaker(s): Seth Hall, MBA, RRT, RRT-ACCS, RRT-NPS, Liquidia Technologies
Session Code: 1055
|
Session Code: 1055
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BA1B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
The PHriendly Neighborhood Pharmacist: Mapping the Pharmacist’s Role in Pulmonary Hypertension Care Teams
Speaker(s): Diana Gritsenko, PharmD, BCCCP, Liquidia
Session Code: 1072
|
Session Code: 1072
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BC1B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Trends and Disparities in mortality from pulmonary hypertension amongst the population in the U.S., 1999–2020: A CDC WONDER Analysis
Speaker(s): Owais Ahmad, MD, Charles Univeristy
Session Code: 1027
|
Session Code: 1027
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Session Code: 1024
|
Session Code: 1024
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
UNEXPECTED POTENTIALLY HARMFUL EFFECT OF THE SODIUM GLUCOSE COTRANSPORTER TYPE 2 INHIBITOR DAPAGLIFLOZIN IN A MOUSE MODEL OF COPD- ASSOCIATED PULMONARY HYPERTENSION
Speaker(s): Seyedali Mousavi Aghdas, MD, National Jewish Health
Session Code: 1067
|
Session Code: 1067
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B11B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Understanding Early Experiences with Inhaled Prostacyclin Treatment
Speaker(s): Savan Patel, MS, Liquidia Technologies
Session Code: 1061
|
Session Code: 1061
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B81B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Understanding patient experiences, challenges, and emotions during diagnosis of PH-ILD: A qualitative study
Speaker(s): Jennalyn Mayeux, DNP, APRN, NP-C, University of Utah
Session Code: 1039
|
Session Code: 1039
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 BA1B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Understanding patient perspectives on patient engagement in pulmonary arterial hypertension (PAH) care journey to improve shared decision-making: a modified Delphi panel
Speaker(s): Denise Sese, MD, Medical University of South Carolina
Session Code: 1081
|
Session Code: 1081
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Understanding the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis
Speaker(s): Kristin Highland, MD, MSCR, Cleveland Clinic
Session Code: 1040
|
Session Code: 1040
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B61B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Unilateral pulmonary vein atresia: Natural history after 3 years and evolution of pulmonary hemodynamics
Speaker(s): Melissa Diamond, MD, Joe DiMaggio Children's Hospital
Session Code: 1045
|
Session Code: 1045
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B31B0FB6-4F84-F011-8101-8147A53E1DD0 B71B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Use of PICC (Peripherally Inserted Central Catheter) for long-term intravenous prostanoid infusion in Pulmonary Arterial Hypertension. Benefits and complications.
Speaker(s): Alejandro Javier Lescano, AJL., Sanatorio de La Trinidad Mitre
Session Code: 1026
|
Session Code: 1026
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
VRN131326: A selective PDGFR inhibitor ameliorates pulmonary arterial hypertension as a monotherapy and in combination with sotatercept in preclinical models
Speaker(s): Kwangwoo Hwang, Ph.D., Voronoi, Inc. Jae Young Ahn, MFE, Voronoi USA, Inc.
Session Code: 1029
|
Session Code: 1029
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B41B0FB6-4F84-F011-8101-8147A53E1DD0 CB1B0FB6-4F84-F011-8101-8147A53E1DD0 |
||||
|
|
Virtual Care - Can technology support the titration by an Advanced Nurse Practitioner of parenteral prostacyclin in the home?
Speaker(s): Caitriona Minnock, ANP, Mater Misericordia Hospital Dublin
Session Code: 1001
|
Session Code: 1001
|
001 |
CE8314FB-9048-F111-8104-DAE5E73D7F08 B21B0FB6-4F84-F011-8101-8147A53E1DD0 B91B0FB6-4F84-F011-8101-8147A53E1DD0 CA1B0FB6-4F84-F011-8101-8147A53E1DD0 |
